Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs DENTSPLY SIRONA Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 7.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| HALO | XRAY | |
|---|---|---|
Market Cap | $12.58B | $1.73B |
Volume | 2,179,278 | 6,198,582 |
Sector | Health | Health |
52-Week High | $115.22 | $14.68 |
52-Week Low | $61.63 | $8.52 |
Typical Hold Time | 1 Days | 72 Days |
Enterprise Value | $14.49B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
